MARKET

HBIO

HBIO

Harvard
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
-0.080
-1.87%
After Hours: 4.200 0 0.00% 16:00 01/21 EST
OPEN
4.290
PREV CLOSE
4.280
HIGH
4.320
LOW
4.162
VOLUME
67.37K
TURNOVER
--
52 WEEK HIGH
4.650
52 WEEK LOW
1.390
MARKET CAP
163.70M
P/E (TTM)
-24.3337
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Nanopore Platform Market impact of COVID-19 on Share, Size 2021 Movements by Growth Status, Trend Analysis, Revenue Expectation to 2025 Research Report by Research Reports World
Jan 20, 2021 (The Expresswire) -- Global "Nanopore Platform Market" 2021 exploration gives a blueprint of the business with requests, applications and...
The Express Wire · 1d ago
Could The Harvard Bioscience, Inc. (NASDAQ:HBIO) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Harvard Bioscience, Inc. ( NASDAQ:HBIO ) can tell us which group is most powerful. Large...
Simply Wall St. · 6d ago
Electroporation Instruments Market SIze 2021 – Analysis by Market Dynamics and Trends, Forthcoming Developments, Leading Players Update, Emerging Growth, Global Share Forecast to 2024 Report by Industry Research.co
Jan 11, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Electroporation Instruments...
The Express Wire · 01/11 09:49
Global Implantable Remote Patient Monitoring Device Market 2020 Analysis by Sales, Demand, Trends, Consumption and Growth, Forecast 2025
Jan 10, 2021 (CDN Newswire via Comtex) -- The latest report entitled Global Implantable Remote Patient Monitoring Device Market 2020 by Manufacturers, Type...
CDN Newswire · 01/10 21:50
Global Implantable Remote Patient Monitoring Device Market 2020 Comprehensive Industry and Vendor Landscape 2025
Jan 10, 2021 (CDN Newswire via Comtex) -- Global Implantable Remote Patient Monitoring Device Market 2020 by Manufacturers, Regions, Type and Application,...
CDN Newswire · 01/10 18:09
Harvard Bioscience secures $65M in new debt facility
Harvard Bioscience ([[HBIO]] +3.7%) has refinanced its debt with the closing of a new $65M credit facility, and provides for a term loan of $40M and a $25M senior revolving credit
Seekingalpha · 12/23/2020 16:00
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Allakos Inc (NAS...
Benzinga · 12/23/2020 13:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HBIO. Analyze the recent business situations of Harvard through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HBIO stock price target is 5.75 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 30.18M
% Owned: 77.44%
Shares Outstanding: 38.98M
TypeInstitutionsShares
Increased
27
2.22M
New
16
-432.69K
Decreased
36
1.98M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.31%
Healthcare Equipment & Supplies
-0.33%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Green
Chief Financial Officer
Michael Rossi
Vice President/General Manager
Kenneth Olson
Lead Director/Independent Director
Bertrand Loy
Vice President/General Manager
Ken Olson
Independent Director
Katherine Eade
Independent Director
Alan Edrick
Independent Director
John Kennedy
Independent Director
Thomas Loewald
Independent Director
Susan Steele
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company's products consist of instruments, consumables and systems that are made up of various individual products.
More

Webull offers kinds of Harvard Bioscience, Inc. stock information, including NASDAQ:HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.